Biomerica, Inc. (NASDAQ:BMRA) – Equities research analysts at B. Riley issued their Q2 2018 EPS estimates for shares of Biomerica in a research report issued to clients and investors on Thursday. B. Riley analyst A. D’silva forecasts that the company will post earnings per share of ($0.04) for the quarter. B. Riley has a “Buy” rating and a $7.50 price objective on the stock. B. Riley also issued estimates for Biomerica’s Q3 2018 earnings at ($0.06) EPS, Q4 2018 earnings at ($0.06) EPS, FY2018 earnings at ($0.19) EPS, FY2019 earnings at ($0.28) EPS, FY2020 earnings at ($0.26) EPS, FY2021 earnings at ($0.05) EPS and FY2022 earnings at $0.65 EPS.

Biomerica (NASDAQ:BMRA) last announced its earnings results on Monday, October 16th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $1.52 million. Biomerica had a negative net margin of 18.19% and a negative return on equity of 22.82%.

Separately, ValuEngine raised shares of Biomerica from a “sell” rating to a “hold” rating in a research report on Saturday, November 4th.

Shares of Biomerica (NASDAQ BMRA) traded down $0.08 during midday trading on Monday, reaching $4.40. 13,700 shares of the company were exchanged, compared to its average volume of 20,650. Biomerica has a one year low of $1.93 and a one year high of $4.60. The stock has a market cap of $38.51, a PE ratio of -33.85 and a beta of 6.22.

COPYRIGHT VIOLATION WARNING: “Q2 2018 Earnings Estimate for Biomerica, Inc. (BMRA) Issued By B. Riley” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at

About Biomerica

Biomerica, Inc is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores).

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.